Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Join Channel
Consolidated Standalone

Beta Drugs

₹1192.3 0 | 0%

WEBSITE BSE:0 NSE : 17 May, 00:00

Market Cap ₹1146 Cr.

Stock P/E 0.0

P/B 7.3

Current Price ₹1192.3

Book Value ₹ 163.4

Face Value 10

52W High ₹1595

Dividend Yield 0%

52W Low ₹ 660

Edit Ratio

Beta Drugs Research see more...

Stocx User

What factors are likely to support Beta Drugs Limited? Let's explore!

Overview Inc. Year: 2005Industry: Pharmaceuticals & Drugs

Beta Drugs Ltd develops, manufactures, and trades in oncology drugs in India. It offers oncology merchandise, which encompass injections, capsules, and drugs. The employer also provides oncology active pharmaceuticals elements. In addition, it engages within the contract manufacturing activities. The organization serves company hospitals and authorities establishments. It exports its merchandise to approximately 16 countries internationally. Beta Drugs Limited became integrated in 2005 and is centered in Panchkula, India

Read More..

Beta Drugs Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Beta Drugs Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Beta Drugs Profit & Loss

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 51 66 91 116 184 227
Other Income 0 0 0 1 1 1
Total Income 51 66 91 117 185 228
Total Expenditure 41 54 73 91 141 174
Operating Profit 10 12 18 25 43 54
Interest 1 1 3 2 2 2
Depreciation 2 3 4 7 7 10
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 7 8 12 16 34 41
Provision for Tax 0 -0 3 4 9 10
Profit After Tax 7 8 9 12 25 31
Adjustments 0 0 0 0 0 0
Profit After Adjustments 7 8 9 12 25 31
Adjusted Earnings Per Share 7.8 9.3 9.8 12.2 25.8 32

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 23% 36% 35% 0%
Operating Profit CAGR 26% 44% 40% 0%
PAT CAGR 24% 51% 35% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 57% 64% 66% NA%
ROE Average 29% 26% 24% 23%
ROCE Average 34% 31% 26% 25%

Beta Drugs Balance Sheet

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 33 41 57 69 92 123
Minority's Interest 0 0 0 0 0 0
Borrowings 3 7 10 11 12 7
Other Non-Current Liabilities 0 2 3 4 4 4
Total Current Liabilities 14 33 38 37 55 70
Total Liabilities 50 83 108 120 163 204
Fixed Assets 13 18 44 40 55 63
Other Non-Current Assets 4 22 7 9 5 7
Total Current Assets 32 44 57 71 103 134
Total Assets 50 83 108 120 163 204

Beta Drugs Cash Flow

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 12 3 5 10 17
Cash Flow from Operating Activities 17 0 8 19 30 23
Cash Flow from Investing Activities -11 -21 -15 -6 -22 -19
Cash Flow from Financing Activities 5 12 9 -8 -1 -2
Net Cash Inflow / Outflow 12 -9 2 5 7 2
Closing Cash & Cash Equivalent 12 3 5 10 17 19

Beta Drugs Ratios

# Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 7.82 9.3 9.79 12.2 25.82 31.95
CEPS(Rs) 9.96 12.58 13.7 19.35 33.37 42.78
DPS(Rs) 0 0 0 0 0 0
Book NAV/Share(Rs) 38.02 47.31 59.41 71.37 96.05 127.82
Core EBITDA Margin(%) 18.7 17.91 19.72 21.31 23.23 23.39
EBIT Margin(%) 15.52 14.16 16.03 15.82 19.69 19.14
Pre Tax Margin(%) 13.52 11.99 13.18 13.74 18.66 18.08
PAT Margin (%) 13.38 12.19 10.37 10.1 13.51 13.53
Cash Profit Margin (%) 17.04 16.5 14.51 16.02 17.45 18.11
ROA(%) 13.64 12.1 9.82 10.26 17.53 16.74
ROE(%) 20.57 21.79 19.21 18.65 30.85 28.55
ROCE(%) 19.36 18.41 20.71 22.17 36.38 33.94
Receivable days 104.25 109.26 114.47 103.42 78.48 86.71
Inventory Days 20.24 34.14 43.97 44.62 38.24 42.67
Payable days 81.98 104.95 113.58 108.61 101.32 124.66
PER(x) 16.11 11.26 4.08 9.84 21.9 19.62
Price/Book(x) 3.31 2.21 0.67 1.68 5.89 4.9
Dividend Yield(%) 0 0 0 0 0 0
EV/Net Sales(x) 2.07 1.63 0.61 1.05 2.98 2.66
EV/Core EBITDA(x) 10.8 8.8 3.04 4.85 12.59 11.21
Net Sales Growth(%) 0 30.38 37.73 27.88 58.31 23.54
EBIT Growth(%) 0 18.95 55.92 26.18 97.06 20.09
PAT Growth(%) 0 18.87 17.11 24.53 111.76 23.73
EPS Growth(%) 0 18.87 5.36 24.53 111.76 23.73
Debt/Equity(x) 0.23 0.49 0.4 0.25 0.22 0.17
Current Ratio(x) 2.39 1.32 1.51 1.95 1.87 1.93
Quick Ratio(x) 2.36 1.07 1.21 1.57 1.47 1.49
Interest Cover(x) 7.74 6.52 5.63 7.59 19.06 18
Total Debt/Mcap(x) 0.07 0.22 0.59 0.15 0.04 0.03

Beta Drugs Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 66.71 66.71 66.71 66.71 66.71 66.73 66.73 66.73 66.73 66.73
FII 0.29 0 0.29 0.29 0.29 0.29 0.29 0.32 0.32 0.32
DII 0 0.29 0 0.04 0 0 0 0 0 0.04
Public 33 33 33 32.96 33 32.97 32.97 32.95 32.94 32.9
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 34% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26%
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend.
  • Debtor days have increased from 101.32 to 124.66days.
  • Stock is trading at 7.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Beta Drugs News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!